TUCSON,
Ariz., Jan. 16, 2024 /PRNewswire/ -- Accelerate
Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced
the launch of a proposed underwritten public offering of 4,500,000
units, each consisting of one share of common stock and one warrant
to purchase one share of common stock, or for certain investors,
pre-funded units in lieu thereof, with each pre-funded unit
consisting of one-pre-funded warrant to purchase one share of
common stock and one warrant to purchase one share of common stock,
pursuant to a registration statement on Form S-1 filed with the
U.S. Securities and Exchange Commission (the "SEC"). The Company
expects to grant the underwriters a 30-day option to purchase up to
an additional 675,000 shares of common stock and/or additional
warrants to purchase up to 675,000 shares of common stock, in any
combination thereof, at the public offering price, less
underwriting discounts and commissions. The proposed public
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be completed
or the actual size or terms of the offering.
William Blair & Company,
L.L.C. is acting as the sole book-running manager for the offering
and Craig-Hallum Capital Group LLC is acting as co-manager for the
offering.
The proposed offering will be made only by means of a
prospectus. When available, copies of the preliminary prospectus
relating to the proposed offering may be obtained from:
William Blair & Company, L.L.C.
at 150 North Riverside Plaza, Chicago,
Illinois 60606, Attention: Prospectus Department, by
telephone at (800) 621-0687, or by email at
prospectus@williamblair.com.
A registration statement on Form S-1 relating to these
securities has been filed with the SEC but has not yet become
effective. These securities may not be sold, nor may offers to buy
these securities be accepted, prior to the time the registration
statement becomes effective.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in
vitro diagnostics company dedicated to providing solutions
for the global challenges of antibiotic resistance and sepsis. The
Accelerate Pheno® system and Accelerate
PhenoTest® BC kit combine several technologies
aimed at reducing the time clinicians must wait to determine the
most optimal antibiotic therapy for deadly infections. The FDA
cleared system and kit fully automate the sample preparation steps
to report phenotypic antibiotic susceptibility results in
approximately 7 hours direct from positive blood cultures. Recent
external studies indicate the solution offers results 1–2 days
faster than existing methods, enabling clinicians to optimize
antibiotic selection and dosage specific to the individual patient
days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and
"ACCELERATE PHENOTEST" and "ACCELERATE ARC" and "ACCELERATE WAVE"
diamond shaped logos and marks are trademarks or registered
trademarks of Accelerate Diagnostics, Inc.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements,"
including with respect to the proposed offering. No assurance can
be given that the offering discussed above will be completed on the
terms described, or at all. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Any
forward-looking statements in this statement are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. Risks that
contribute to the uncertain nature of the forward-looking
statements include, but are not limited to, those risks and
uncertainties set forth in the Company's registration statement on
Form S-1 filed with the SEC and the preliminary prospectus included
therein. Copies of the registration statement can be accessed by
visiting the SEC website at www.sec.gov. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. The Company undertakes no obligation
to update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-announces-launch-of-proposed-public-offering-302035386.html
SOURCE Accelerate Diagnostics, Inc.